View OpEd: Is the US Quietly Ending COVID-19 Vaccination for the Young and Healthy

View OpEd: https://www.infectioncontroltoday.com/view/is-us-quietly-ending-covid-19-vaccination-young-healthy

References:

1. Longworth N. New FDA seasonal COVID-19 shot guidance seeks ‘evidence based’ approach. Live Now Fox. May 20, 2025. https://www.livenowfox.com/news/new-fda-seasonal-covid-19-shot-guidance-evidence-based-approach-may-2025

2.COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025. U.S. Food & Drug Administration. May 15, 2025. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025

3. Greenfield B. What you need to know about Moderna’s new COVID vaccine, just approved by the FDA. June 2, 2025. https://fortune.com/well/2025/06/02/moderna-new-covid-vaccine-approved-by-fda-what-to-know/

4. U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine. Novavax News & Media. May 19, 2025. br /> &
5. American Heart Association News. Myocarditis from COVID-19 booster rare, but risk highest among teen boys, young men. American Heart Association. Sept. 6, 2025. https://www.heart.org/en/news/2022/09/06/myocarditis-from-covid-19-booster-rare-but-risk-highest-among-teen-boys-young-men

6. UPDATE TO COMIRNATY (COVID-19 VACCINE, mRNA) PRESCRIBING INFORMATION AS OF JUNE 2025. Pfizer. June 2025. https://www.comirnatyhcp.com/

7. Faksova K. Walsh D. Jiang Y. et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. Apr. 2024. https://www.sciencedirect.com/science/article/pii/S0264410X24001270

8. EMA committee recommends marketing approval of Pfizer & BioNTech’s LP.8.1-adapted Covid-19 vaccine. Pharmabiz.com. July 26, 2025. https://www.pharmabiz.com/NewsDetails.aspx?aid=180347&sid=2

9. Kates J. ACIP, CDC, and Insurance Coverage of Vaccines in the United States. KFF. June 13, 2025. https://www.kff.org/other/issue-brief/acip-cdc-and-insurance-coverage-of-vaccines-in-the-united-states/

10. Parseghian A. Florida Surgeon General continues mRNA vaccine criticism, calls for expanded federal research. WTSP-TV Tampa-St. Petersburg. July 21, 2025. https://www.msn.com/en-us/health/other/florida-surgeon-general-continues-mrna-vaccine-criticism-calls-for-expanded-federal-research/ar-AA1IOkfB?ocid=BingNewsSerp

11. Universita Cattolica del Sacro Cuore. "COVID vaccines saved 2. 5M lives globally—a death averted per 5,400 shots." ScienceDaily. ScienceDaily, 27 July 2025. https://sciencedaily.com/releases/2025/07/250726234429.htm

12. About Polio in the United States. CDC. May 9, 2024. https://www.cdc.gov/polio/about/

13. Bager P, Svalgaard IB, Lomholt FK, et al. The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24. Lancet Infect Dis. 2025 Jun;25(6):616-624. doi: 10.1016/S1473-3099(24)00806-5. Epub 2025 Jan 29. PMID: 39892410. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00806-5/fulltext

14. Shingles Facts and Stats. CDC. Apr. 12, 2024. https://www.cdc.gov/shingles/data-research/index.html

15. Pontus Hedberg, Suzanne Desirée van der Werff, Pontus Nauclér, The Effect of COVID-19 Vaccination on the Risk of Persistent Post–COVID-19 Condition: Cohort Study, The Journal of Infectious Diseases, Volume 231, Issue 5, 15 May 2025, Pages e941–e944, https://doi.org/10.1093/infdis/jiaf133

16. Mandel H, Yoo YJ, Allen AJ, et al. Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative, Clinical Infectious Diseases, Volume 80, Issue 6, 15 June 2025, Pages 1247–1261, https://doi.org/10.1093/cid/ciaf046

17. Gross RS, Thaweethai T, Salisbury AL, et al. Characterizing Long COVID Symptoms During Early Childhood. JAMA Pediatr. 2025 May 27;179(7):781–92. doi: 10.1001/jamapediatrics.2025.1066. Epub ahead of print. Erratum in: JAMA Pediatr. 2025 Jul 21. doi: 10.1001/jamapediatrics.2025.2389. PMID: 40554463; PMCID: PMC12117493. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2834480

18. Wu Q, Zhang B, Tong J, et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. EClinicalMedicine. 2024 Dec 6;79:102962. doi: 10.1016/j.eclinm.2024.102962. PMID: 39720603; PMCID: PMC11667630. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00541-8/fulltext

19. Van Beusekom M. Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version. CIDRAP. Apr. 16, 2025. https://www.cidrap.umn.edu/covid-19/novavax-says-its-covid-vaccine-produces-fewer-milder-reactions-pfizer-version

20. Vaxart receives stop work order on government-backed project. Invsting.com. Feb. 24, 2025. https://www.investing.com/news/sec-filings/vaxart-receives-stop-work-order-on-governmentbacked-project-93CH-3886127

21. A New Oral Vaccine Tablet Could Reshape Infectious Disease Prevention. Scientia. Sept. 4, 2024. https://www.scientia.global/a-new-oral-vaccine-tablet-could-reshape-infectious-disease-prevention/

22. Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive. Biospace. July 20, 2022. https://www.biospace.com/vaxart-publishes-clinical-data-suggesting-its-oral-covid-19-pill-vaccine-candidate-induces-long-lasting-mucosal-immune-responses-that-are-highly-cross-reactive

23. Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial. Vaxart Press Release. May 15, 2025. https://investors.vaxart.com/news-releases/news-release-details/vaxart-receives-barda-approval-initiate-dosing-10000-participant